The association of antibodies to β2 glycoprotein I with the antiphospholipid syndrome: A meta-analysis

Annals of Clinical and Laboratory Science

Volumn 27, Issue 1, 1997, Pages 41-46

  Najmey, Sawsan S ^a   Keil, Lynn B ^a   Adib, Deyaa Y R ^a   DeBari, Vincent A ^a,b  

^a SETON HALL UNIVERSITY   (United States)

^b ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BIOCHEMICAL MARKER; LUPUS ANTICOAGULANT;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN CONFORMATION; TARGET CELL;

ANTIBODIES; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; EPITOPES; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; INFORMATION SYSTEMS; LUPUS COAGULATION INHIBITOR; META-ANALYSIS;

EID: 0031014695     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Alarcón-Segovia D, Sanchez-Guerrero J. Primary anti-phospholipid syndrome. J Rheumatol 1989;16:482-8.
2. 2 glycoprotein I antibodies in the antiphospho-lipid syndrome. J Rheumatol 1994;21:1678-83.
3. Eby CS. A review of the hypercoagulable state. In: Penner JA, Hassouna HI, editors. Hematology/ Oncology Clinics of North America 1993;7:1121-42.
4. Fort JG, Cowchock FS, Abruzzo JL, Smith JB. Anticardiolipin antibodies in patients with rheumatic diseases. Arthritis Rheum 1987;30:752-60.
5. Lockshin MD. Antiphospholipid antibody syndrome. In: McCune WJ, editor. Rheumatic Disease Clinics of North America 1994;20:45-59.
6. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
7. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
8. 2-glycoprotein I structure altered by interacting with an oxygen modified solid-phase surface. J Exp Med 1994;179: 457-62.
9. 2-glycoprotein I in the absence of phospholipid. Importance of ag density and bivalent binding. J Immunol 1995;154:954-60.
10. 2 glycoprotein I to activated polystyrene and its recognition by human IgG auto-antibodies. Biotechnol Appl Biochem 1995;22:305-13.
11. DeAngelis C. An Introduction to Clinical Research. New York: Oxford University Press, 1990:43.
12. Glantz SA. Primer of biostatistics: the program v. 3.0 New York: McGraw-Hill, 1992.
13. 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22: 1899-1906.
14. 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995;22:1894-8.
15. 2 glycoprotein I and anticardiolipin antibodies. J Rheumatol 1995;22:2233-7.
16. 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Amer J Med 1992;93:181-6.
17. 2-glycoprotein-I antibodies in monozygotic twin sisters. J Rheumatol 1994;21: 1970-1.
18. Stadel BV. Oral contraceptives and cardiovascular disease (part 2). New Engl J Med 1981;305:672-7.
19. 2-glycoprotein I. Clin Immunol Immunopathol 1994;72:187-92.
20. 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995;73:29-34.
21. 2-glycoprotein I antibody in sera from patients with antiphospholipid syndrome. Rheumatol Int 1995;15:1-8.
22. 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anti-coagulants. Blood 1993;81:1255-62.
23. 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994;83:2878-92.
24. 2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996;75:49-55.
25. 2glycoprotein I antibody on factor Va degradation by activated-protein C and its cofactor protein S. Amer J Hematol 1995;49:89-91.
26. 2-glycoprotein I: preparation, properties and availability to investigators. Clin Chem 1996;42:1116-7.
27. 2-glycoprotein I. Standardized immunoassay and a reference interval for healthy controls. Proc Assoc Am Physicians (in press).